| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1074215457 |
| P356 | DOI | 10.1186/S13052-016-0315-Y |
| P932 | PMC publication ID | 5347813 |
| P698 | PubMed publication ID | 28257631 |
| P50 | author | Pasquale Comberiati | Q57069757 |
| Giovanni Passalacqua | Q61949008 | ||
| Antonella Muraro | Q88011790 | ||
| Carlo Caffarelli | Q90751867 | ||
| Roberto Bernardini | Q114418114 | ||
| Massimo Landi | Q43109632 | ||
| Alessandro Fiocchi | Q37837897 | ||
| P2093 | author name string | Elisabetta Calamelli | |
| Stefania La Grutta | |||
| Alberto Martelli | |||
| Luciana Indinnimeo | |||
| Giovanni Battista Pajno | |||
| Stefania Arasi | |||
| Marzia Duse | |||
| Diego Peroni | |||
| Allergen-specific Immunotherapy panel of the Italian Society of Pediatric Allergy and Immunology (SIAIP) | |||
| P2860 | cites work | Specific allergen immunotherapy for the treatment of atopic eczema | Q24186146 |
| Oral and sublingual immunotherapy for egg allergy | Q24187949 | ||
| Allergen-specific oral immunotherapy for peanut allergy | Q24200573 | ||
| Oral immunotherapy for milk allergy | Q24202867 | ||
| Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers | Q47715881 | ||
| Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis | Q47804869 | ||
| Rhinitis is an independent risk factor for developing cough apart from colds among adults | Q47857935 | ||
| Safety of sublingual immunotherapy with a monomeric allergoid in very young children. | Q47886315 | ||
| Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy | Q47963672 | ||
| Food avoidance in children with adverse food reactions: influence of anxiety and clinical parameters | Q47970624 | ||
| Association between asthma and rhinitis according to atopic sensitization in a population-based study | Q48033561 | ||
| Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy | Q48382282 | ||
| Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis | Q48392845 | ||
| Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy | Q48713439 | ||
| Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet | Q48897904 | ||
| SIT: efficacy depends on product, not on route of application | Q49186569 | ||
| Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. | Q50621222 | ||
| Oral Immunotherapy for Egg Allergy: A Double-Blind Placebo-Controlled Study, with Postdesensitization Follow-Up. | Q51654466 | ||
| Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. | Q51686636 | ||
| A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. | Q51767454 | ||
| How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. | Q51809131 | ||
| Allergen immunotherapy: a practice parameter third update. | Q52712682 | ||
| Oral immunotherapy in cow's milk allergic patients: course and long-term outcome according to asthma status. | Q53636045 | ||
| Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. | Q53644137 | ||
| Specific oral tolerance induction in children with very severe cow's milk–induced reactions | Q57243160 | ||
| Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants | Q57599206 | ||
| Administration of a probiotic with peanut oral immunotherapy: A randomized trial | Q57776766 | ||
| EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy | Q57919564 | ||
| The value of hyposensitization therapy for bronchial asthma in children--a 14-year study | Q72123648 | ||
| The impact of childhood food allergy on quality of life | Q77431896 | ||
| Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children | Q80190687 | ||
| Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study | Q80417919 | ||
| Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review | Q80551968 | ||
| Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis | Q81025110 | ||
| Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years | Q81301079 | ||
| Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study | Q82340072 | ||
| Disease-modifying effect and economic implications of sublingual immunotherapy | Q82539180 | ||
| Importance of patient's education in favouring compliance with sublingual immunotherapy | Q83081674 | ||
| SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial | Q83346456 | ||
| Adverse reactions to immunotherapy are associated with different patterns of sensitization to grass allergens | Q86618493 | ||
| Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy | Q39309227 | ||
| Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study | Q39581669 | ||
| Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy | Q40035890 | ||
| Airborne pollen levels and drug consumption for seasonal allergic rhinoconjunctivitis: a 10-year study in France. | Q40191844 | ||
| Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. | Q40403475 | ||
| Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. | Q40476204 | ||
| Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | Q40523833 | ||
| Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 | ||
| Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects | Q40893594 | ||
| A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma | Q41480097 | ||
| Cow's milk allergy in children and adults | Q41709814 | ||
| Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study | Q42595535 | ||
| Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study | Q42678089 | ||
| Adherence to sublingual immunotherapy in preschool children | Q43502504 | ||
| Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. | Q43724345 | ||
| Rhinitis and onset of asthma: a longitudinal population-based study | Q43995099 | ||
| Changing the route of immunotherapy administration: an 18-year survey in pediatric patients with allergic rhinitis and asthma | Q44192989 | ||
| Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial | Q44961338 | ||
| Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba | Q45222536 | ||
| Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy | Q45874463 | ||
| Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language | Q46632369 | ||
| Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice | Q46787767 | ||
| Injection allergen immunotherapy for asthma | Q24236566 | ||
| Allergen injection immunotherapy for seasonal allergic rhinitis | Q24243115 | ||
| Challenges in coding adverse events in clinical trials: a systematic review | Q26851713 | ||
| State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous | Q28236045 | ||
| Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel | Q28300001 | ||
| Improving the safety of immunotherapy | Q30217155 | ||
| Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment | Q30217497 | ||
| EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy | Q30394524 | ||
| Sublingual immunotherapy: World Allergy Organization position paper 2013 update | Q30440195 | ||
| Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature | Q33204109 | ||
| Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study | Q34005065 | ||
| Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System | Q34097796 | ||
| Duration of a cow-milk exclusion diet worsens parents' perception of quality of life in children with food allergies. | Q34520523 | ||
| Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials | Q34561153 | ||
| The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. | Q34617096 | ||
| Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization | Q34640733 | ||
| Clinical contraindications to allergen immunotherapy: an EAACI position paper | Q34669524 | ||
| A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response | Q34698506 | ||
| Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper | Q34754637 | ||
| Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies | Q35186257 | ||
| Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score | Q35761230 | ||
| Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: avoidance of indoor allergens | Q35831636 | ||
| Atopic march: link to upper airways. | Q36005779 | ||
| Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review | Q36062618 | ||
| Oral immunotherapy for treatment of egg allergy in children | Q36180099 | ||
| Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial | Q36548283 | ||
| Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. | Q36555170 | ||
| Regulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach | Q36834860 | ||
| Today's allergic rhinitis patients are different: new factors that may play a role | Q36904987 | ||
| Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. | Q36977154 | ||
| Allergen specific immunotherapy for atopic dermatitis | Q36995977 | ||
| A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy | Q37150568 | ||
| Economic studies of immunotherapy: a review | Q37318081 | ||
| A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. | Q37325838 | ||
| Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses | Q37389177 | ||
| Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions | Q37390810 | ||
| A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics | Q37418202 | ||
| Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. | Q37425021 | ||
| Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. | Q37802050 | ||
| Regulatory environment for allergen-specific immunotherapy | Q37834696 | ||
| Specific immunotherapy: beyond the clinical scores | Q37948356 | ||
| Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. | Q37948357 | ||
| Oral immunotherapy for cow's milk allergy | Q38002333 | ||
| Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report | Q38090066 | ||
| Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. | Q38104457 | ||
| Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review | Q38104712 | ||
| Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. | Q38109313 | ||
| Molecular profile clustering of IgE responses and potential implications for specific immunotherapy | Q38116892 | ||
| The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy | Q38124403 | ||
| Molecular diagnosis and immunotherapy | Q38144677 | ||
| Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy | Q38265953 | ||
| Potential treatments for food allergy | Q38280377 | ||
| Sublingual immunotherapy: focus on tablets | Q38540289 | ||
| International consensus on allergy immunotherapy. | Q38544969 | ||
| Variation in allergen content in sublingual allergen immunotherapy with house dust mites | Q38549315 | ||
| Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report | Q38587115 | ||
| Update on immunotherapy for the treatment of asthma | Q38647353 | ||
| Allergen Immunotherapy: History and Future Developments | Q38652613 | ||
| Oral Immunotherapy for Food Allergy | Q38652624 | ||
| The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions | Q38753106 | ||
| Molecular diagnosis and precision medicine in allergy management | Q38777960 | ||
| Food allergen immunotherapy: Current status and prospects for the future | Q38802445 | ||
| Atopic dermatitis and filaggrin | Q38804074 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pediatrics | Q123028 |
| Italy | Q38 | ||
| atopic dermatitis | Q268667 | ||
| food allergy | Q769815 | ||
| immunotherapy | Q1427096 | ||
| allergen immunotherapy | Q1641412 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 13 | |
| P577 | publication date | 2017-01-23 | |
| P1433 | published in | Italian Journal of Paediatrics | Q15762169 |
| P1476 | title | Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report | |
| P478 | volume | 43 |
| Q55334503 | A critical appraisal on AIT in childhood asthma. |
| Q57175663 | Advances in pediatrics in 2017: current practices and challenges in allergy, endocrinology, gastroenterology, genetics, immunology, infectious diseases, neonatology, nephrology, neurology, pulmonology from the perspective of Italian Journal of Pediat |
| Q64241568 | Chronic urticaria and drug hypersensitivity in children |
| Q47713994 | Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients |
| Q64241579 | Drug desensitization in allergic children |
| Q58745882 | IgE-mediated food allergy |
| Q58729387 | Immunotherapy and Asthma in Children |
| Q92643892 | Management of chronic urticaria in children: a clinical guideline |
| Q51351972 | Pediatric respiratory tract diseases: Chronological trends and perspectives. |
| Q52691764 | Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment. |
| Q90333566 | Pollen-Food Allergy Syndrome: A not so Rare Disease in Childhood |
| Q90751873 | Report on advances for pediatricians in 2018: allergy, cardiology, critical care, endocrinology, hereditary metabolic diseases, gastroenterology, infectious diseases, neonatology, nutrition, respiratory tract disorders and surgery |
| Q92599658 | Risk factors analysis of attention deficit/hyperactivity disorder and allergic rhinitis in children: a cross-sectional study |
| Q52571991 | SLIT's Prevention of the Allergic March. |
| Q59797385 | Solid Food Introduction and the Development of Food Allergies |
| Q33586188 | Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children |
| Q55662210 | The future outlook on allergen immunotherapy in children: 2018 and beyond. |
Search more.